MDMA (ecstasy) pharmacokinetics in a CYP2D6 poor metaboliser and in nine CYP2D6 extensive metabolisers

This publication has 16 references indexed in Scilit:

• Serotonergic Neurotoxic Metabolites of Ecstasy Identified in Rat Brain
  The Journal of Pharmacology and Experimental Therapeutics, 2005
• Repeated doses administration of MDMA in humans: pharmacological effects and pharmacokinetics
  Psychopharmacology, 2004
• Multiple toxicity from 3,4-methylenedioxymethamphetamine (“ecstasy”)
  The American Journal of Emergency Medicine, 2003
• Neuroendocrine abnormalities in recreational ecstasy (MDMA) users: is it ecstasy or cannabis?
  Biological Psychiatry, 2002
• The effect of 3,4‐methylenedioxymethamphetamine (MDMA, ?ecstasy?) and its metabolites on neurohypophysial hormone release from the isolated rat hypothalamus
  British Journal of Pharmacology, 2002
• 3,4-Dihydroxymethamphetamine (HHMA). A Major in Vivo 3,4-methylenedioxymethamphetamine (MDMA) Metabolite in Humans
  Chemical Research in Toxicology, 2001
• Cardiovascular and Neuroendocrine Effects and Pharmacokinetics of 3,4-Methylenedioxymethamphetamine in Humans
  The Journal of Pharmacology and Experimental Therapeutics, 1999
• The hyperthermic and neurotoxic effects of ‘Ecstasy’ (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype
  British Journal of Pharmacology, 1995
• Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology
  Pharmacogenetics, 1995
• Polymorphic dextromethorphan metabolism: Co-segregation of oxidative O-demethylation with debrisoquin hydroxylation
  Clinical Pharmacology & Therapeutics, 1985